Pharmaceuticals 2012, 5(5), 469-480; doi:10.3390/ph5050469
Review

Newer Anticoagulants for Non-Valvular Atrial Fibrillation

Received: 29 March 2012; in revised form: 28 April 2012 / Accepted: 28 April 2012 / Published: 4 May 2012
(This article belongs to the Special Issue Anticoagulants)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Non-valvular atrial fibrillation is a recognized risk factor for stroke and systemic embolism. It has been clearly established that warfarin reduces the risk of stroke and systemic embolism in persons with atrial fibrillation and additional risk factors for stroke. The use of warfarin, however, requires frequent monitoring, and there is great variability in patient response to warfarin. Warfarin interacts with several medications and foods. In addition, warfarin use portends a significant risk of bleeding. For these reasons, warfarin is frequently not prescribed to persons for whom the drug would provide a clear benefit. Over the past decade, attempts have been made to develop drugs that are at least as safe and effective as warfarin for the treatment of atrial fibrillation that do not require monitoring nor have as many interactions. Initial studies of compounds in this regard ultimately failed due to safety concerns, but over the past two years two novel agents have been approved by the United States Food and Drug Association for anticoagulation in non-valvular atrial fibrillation, another drug is under review, and additional compounds are being studied. This article will review the use of warfarin and these new agents in the treatment of non-valvular atrial fibrillation.
Keywords: atrial fibrillation; warfarin; anticoagulation; stroke; systemic embolism
PDF Full-text Download PDF Full-Text [198 KB, uploaded 4 May 2012 11:51 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Harburger, J.M.; Aronow, W.S. Newer Anticoagulants for Non-Valvular Atrial Fibrillation. Pharmaceuticals 2012, 5, 469-480.

AMA Style

Harburger JM, Aronow WS. Newer Anticoagulants for Non-Valvular Atrial Fibrillation. Pharmaceuticals. 2012; 5(5):469-480.

Chicago/Turabian Style

Harburger, Joseph M.; Aronow, Wilbert S. 2012. "Newer Anticoagulants for Non-Valvular Atrial Fibrillation." Pharmaceuticals 5, no. 5: 469-480.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert